Digital therapeutics (DTx): a new medical toolkit for the agent’s portfolio
Digital therapeutics (DTx) are a category of medical treatments based on high-quality software that is clinically evaluated and, where required, cleared or certified by regulators. They are designed to prevent, manage, or treat a wide range of physical, mental, and chronic conditions.
For insurance agents, the key difference to understand before talking to clients is this: general wellness apps mostly track habits or routines, such as counting steps or logging calories, while DTx deliver therapeutic interventions grounded in scientific evidence. DTx are designed to produce a direct, measurable clinical benefit for the patient, which is why they are sometimes described as “software-based medicine.” They can be used on their own or alongside medication and other therapies, and they do not replace a doctor’s care.
This article looks at how DTx differ from traditional tools, how they can support treatment adherence, and how to build sales arguments that reflect the shift toward digitalization in insurance, a field where digital health ecosystems play an increasingly important role in supporting good clinical outcomes.
ÍNDICE DEL ARTÍCULO
How do digital therapeutics change an insurance agent’s day-to-day work?
Bringing DTx into the insurance market is not just a technology upgrade; it changes how agents communicate their value proposition. An agent who masters this concept stops being a policy seller who only reacts to client requests and becomes a forward-looking digital health advisor.
The competitive edge of scientific evidence
Today’s clients are better informed than ever and expect real solutions. Offering a solution backed by rigorous clinical trials can give agents an advantage over competitors who offer generic coverage. As the Digital Therapeutics Alliance explains, products that call themselves digital therapeutics are expected to publish trial results with clinically meaningful outcomes and to be reviewed and cleared or certified by regulators, as required, to support their claims.
The agent’s role in sales is shifting, from simply explaining premiums to offering real strategic advice. By bringing the digital health ecosystem into sales conversations, an agent becomes a trusted advisor who offers practical tools for the policyholder’s well-being.

Impact on the business: the loss ratio
One of an agent’s biggest challenges is managing the loss ratio of their book of business. This is where DTx can help:
- Treatment adherence: digital tools may help patients follow their treatment. A 2025 review in Frontiers in Pharmacology found that digital interventions can increase adherence, but results are mixed and many interventions failed to improve it, so the evidence for each product matters.
- Fewer crises: better adherence may mean fewer relapses and unplanned emergency visits, and, over time, lower medical costs, although evidence of savings is still limited.
- Policy sustainability: containing medical costs could improve how a policy performs financially, which can support renewals.
Practical application: how to bring digital therapeutics into the sales strategy
Knowing what DTx are has limited value unless that knowledge is built into the sales funnel. In conversations with prospects, the goal is to translate technical features into tangible benefits for their health and financial peace of mind.

Identifying opportunities with big data
Big data analysis, used with client consent and in line with data protection rules, can help agents spot in advance which clients are most likely to value an advanced digital health offering. For example:
- Policyholders concerned about a family history of chronic disease.
- Clients with pre-existing conditions that need closer monitoring.
- Young, tech-savvy prospects who want more control over their health.
Ongoing support as a selling point
Because DTx run on software, they can give patients ongoing, personalized support between medical appointments. Explaining this to clients shows them that their policy is not just there for emergencies; it can also support their care day by day. Coverage of DTx varies by policy and by country, so it is worth confirming what each plan includes.
Bringing this approach into client meetings sets agents apart from traditional advisors and moves the conversation toward more specialized advice.
Retention strategies and conversation tactics
To put this into practice, agents can adapt their conversations and strengthen client retention strategies with specific actions:
- Discovery phase: asking about chronic conditions and long-term health concerns while identifying the client’s needs, so that DTx can be presented as a useful complement.
- Value positioning: presenting DTx as a medical service, not a free app, something clients carry with them every day and, where required, cleared or certified by regulators.
- Real examples: explaining how the software helps patients avoid crises. Some products, for instance, track symptoms and send preventive alerts. This makes an abstract idea concrete.
- Reinforcement at renewal: reminding clients of the progress digital support has brought to reinforce the value of their coverage.
A new standard in health
Digital therapeutics are more than a passing trend; they are a new medical toolkit in the agent’s portfolio. Mastering this topic allows agents to:
- Stand out from advisors who compete only on price.
- Offer a value proposition built on prevention and clinical benefit.
- Build a long-term relationship of trust with clients who feel supported every day.
Ultimately, the ability to explain how software is being used to treat conditions “beyond pills” can establish an agent as a leader in the health insurance market. The agent of the future does not just sell insurance; they help clients navigate digital health ecosystems that support better health outcomes.
Digital therapeutics are not a substitute for professional medical care. Clients should always follow their health professional’s advice, and agents should avoid making medical claims or promising outcomes. The availability, regulatory status, and coverage of DTx vary by country and by plan.
Sources:
- Digital Therapeutics Alliance. (2019). Digital therapeutics definition and core principles [Fact sheet]. https://dtxalliance.org/wp-content/uploads/2021/01/DTA_DTx-Definition-and-Core-Principles.pdf
- Moon, Z., & Walsh, J. (2025). Digital interventions in medication adherence: a narrative review of current evidence and challenges. Frontiers in Pharmacology. https://www.frontiersin.org/articles/10.3389/fphar.2025.1632474/full